BMP Meeting about Patient Reported Outcome Measures in EU Parliament
"Optimising Patient Relevant Outcome Measures for sustainable healthcare systems and strong economies"
A session was organized by the Brain, Mind and Pain (BMP) Interest Group of the European Parliament on “Optimising Patient Relevant Outcome Measures for sustainable healthcare systems and strong economies”.
Keynote Addresses were presented by Laure Delbecque, Associate Director of Pharmerit International, who pointed out that Quality of life (Qol) questionnaires should be based on patient interviews and Anna Graca, Programm and Policy Officer at the European Commission, who presented the new programm “Horizon Europe”.
Grünenthal’s Chief Commercial Officer Mark Fladrich spoke as a panelist and strengthened Grünenthal’s active engagement in involving patients from early on in our clinical trials set-up. He also mentioned the public-private partnership IMI (Innovative Medicines Initiative) and the multi-stakeholder platform SIP (Societal Impact of Pain) as perfect examples of reform in the patient-centered measured outcomes.
Kaisa Immonen, Policy Director of European Patients’ Forum, stated that Patient Outcome Measure are not enough to be reported, they should be prioritised. This led to a discussion with the other panelist, the outcome of which was that this practice should be implemented into clinical trials, investigator initiated trials (IITs) and all other initiatives.
About 100 participants from multiple stakeholder organisations participated in this interactive Event in the European Parliament.